NEW YORK (GenomeWeb News) – Nottingham, UK-based CompanDx and Clinical Reference Laboratory announced that they will collaborate on the development of biomarker panels and companion diagnostics for pharmaceutical, biotech, and academic clients worldwide.
Under the terms of the multi-year agreement, CompanDX said it will continue bioinformatics work on its Distiller platform, which includes the development of its "Time to Event" breast cancer signature supported by CRL's CLIA-certified laboratory services. Financial and other terms of the alliance were not disclosed.
"Clients are looking for our help to support their clinical development programs either by reducing the complexity of genomic or proteomic data or by proving innovative MDx tests that will allow them to stratify clinical trials," CompanDx CEO Andy Sutton said in a statement. "CRL brings a level of expertise in the design and delivery of MDx tests that ideally compliments our innovative approach."